View Post

The Next-Generation Promise of ADCs and SERDs in Breast Cancer

In In The News by Barbara Jacoby

By: Lisa Astor From: targetedonc.com The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer. In 2022, development of novel targeted therapies has focused on antibody-drug conjugates (ADCs) and selective estrogen receptor degraders (SERDs). Both classes of agents have shown mixed efficacy over time. The generation in development offers reasons for excitement about improved …

View Post

Triple-Negative Breast Cancer Treatments Continue to Evolve

In In The News by Barbara Jacoby

By: HAYLEY VIRGIL From: oncnursingnews.com Beyond single-agent chemotherapy, few effective treatment options are available for metastatic triple-negative breast cancer (TNBC), according to Candace Mainor, MD, but several approaches comprised of immunotherapy, antibody-drug conjugates (ADCs), and PARP inhibitors are shifting standards of care and eliciting impressive response rates in heavily pretreated patients. “There are some exciting new therapies for the treatment …